Insight into the Recent Advancement of 1,3,4 Oxadiazoles as Potential EGFR and Telomerase Inhibitory for Anticancer Activity
Ayush Jain1,2, Chandana Majee2★, Rupa Mazumder2, Avijit Mazumder2★ Corresponding author
- 1Department of Pharmacy, HIMT College of Pharmacy, Greater Noida, Uttar Pradesh, INDIA.
- 2Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, INDIA.
CORRESPONDENCE
Chandana Majee
Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida, Uttar Pradesh, INDIA.
Received: 08-01-2026; Revised: 18-03-2026; Accepted: 27-04-2026.
Volume 60, Issue 3S · pp. s882–s895 · PUBLISHED 2026 · DOI: 10.5530/ijper.20261459
ABSTRACT
Cancer is acknowledged as one of most perilous diseases, with significant challenges associated with existing anticancer therapies, including issues of drug resistance, narrow therapeutic windows, and the manifestation of severe and diverse adverse effects. Given the current state of oncology research, there is an urgent need to drive the development of innovative anticancer therapeutics that target unique molecular pathways to enhance the effective management of cancer. In this context, targeting the Epidermal Growth Factor Receptor (EGFR) and telomerase inhibition emerges as a promising strategy, with ongoing investigation focusing on 1,3,4-oxadiazole derivatives for this purpose. The findings of diverse researchers investigating these molecular frameworks have been systematically reviewed and analysed, culminating in a comprehensive summary. This review is centered on elucidating the Structure-Activity Relationships (SARs) and computational analyses of a range of 1,3,4-oxadiazole derivatives, specifically focusing on documented cytotoxicity, EGFR-TK inhibitory potential, and their efficacy as telomerase inhibitors in the context of anticancer activity. 1,3,4-Oxadiazole hybrids/derivatives with diverse substitutions exhibit efficacy as pharmacophores in achieving robust anticancer effects. Following a comprehensive literature survey, it is concluded that this review will undoubtedly furnish researchers with substantial insights to facilitate the design and synthesis of potent hybrids/derivatives capable of inhibiting EGFR and telomerase, thereby enhancing their therapeutic potential against cancer.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Jain, A., Majee, C., Mazumder, R., & Mazumder, A. (2026). Insight into the Recent Advancement of 1,3,4 Oxadiazoles as Potential EGFR and Telomerase Inhibitory for Anticancer Activity. Indian Journal of Pharmaceutical Education and Research, 60(3S), s882–s895. https://doi.org/10.5530/ijper.20261459
